BS Summary: This article contains 8 faulty reasoning types, including Optimism Bias, Anchoring Bias, and Availability Heuristic, with Framing Effect as the most egregious example at 70.9% saturation with 249 hits. Analysis detected 619 faulty-reasoning hits from 351 analyzed words, generating a BS Score of 81.6% and a BS Rank of 88% (2,075 of 16,813 articles). This article is worse (more manipulative) than 87.70% of the article peer group.
President Trump said the administration has reached agreements with nine more drugmakers to bring their U.S. drug prices more in line with what other wealthy countries pay.
Fourteen companies in total have now reached what the administration calls most-favored-nation pricing deals.
The companies that took part in Friday's announcement were: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.
They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries.
The agreements will allow state Medicaid programs to access lower prices from the nine companies.
In a statement, the White House said the change will result "in billions of dollars in savings."
The drugmakers also agreed to invest at least $150 billion in manufacturing operations in the U.S.
The president is seeking to increase domestic production of pharmaceuticals.
In addition, the companies agreed to make some of their most popular drugs available at lower prices to consumers who pay out of pocket through a government website called TrumpRx.com.
The TrumpRx website is expected to launch in early 2026, and would take consumers to pharmaceutical companies' direct-to-consumer websites to fulfill orders.
For example, Merck will reduce the price of Januvia, a medication for Type 2 diabetes, from $330 to $100 for patients purchasing directly through TrumpRx, the White House said.
Amgen will reduce the price of Repatha, a cholesterol-lowering drug, from $573 to $239 when purchased through TrumpRx.
In exchange for these concessions, the companies will be exempt from possible administration tariffs for three years.
The extent of savings for consumers under the agreements is unclear.
Medicaid and its beneficiaries already pay some of the lowest prices for drugs.
And people with health insurance could spend less on copays for their medicines than paying cash for them through the drugmakers.
Separately, Trump said during the press event that he would like to get health insurers to lower their prices, too.
"I'm going to call a meeting of the insurance companies," he said.
"I'm going to see if they [will] get their price down, to put it very bluntly."
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.